By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



394 Lowell Street, Suite

Lexington   Massachusetts     U.S.A.
Phone: n/a Fax: n/a



Company News
Alzheon Announces Phase 1 Results Of ALZ-801, A First-in-Class Inhibitor Of Amyloid Formation And Neurotoxicity For Alzheimer’s Disease 3/20/2015 10:20:19 AM
Alzheon Announces Patent Allowance In Europe For ALZ-801 In Development For Alzheimer’s Disease 1/5/2015 10:19:53 AM
Alzheon Appoints David Nikodem, Ph.D., To Board Of Directors 1/5/2015 9:30:51 AM
Alzheon Appoints Renowned Industry Leader, Jean-Pierre Sommadossi, PhD, To Board Of Directors 8/5/2014 10:01:58 AM
Alzheon To Participate in Global Dementia Legacy Meeting to Increase Investment in Dementia 6/16/2014 9:44:24 AM
Alzheon To Participate In Global Dementia Legacy Meeting To Increase Investment In Dementia 6/16/2014 9:12:59 AM
Alzheon Announces Notice Of Allowance For U.S. Patent For Its Lead Drug Candidate ALZ-801 In Clinical Development For Alzheimer’s Disease 4/15/2014 9:16:43 AM
Alzheon Appoints Franz Hefti, PhD, To Board Of Directors 4/15/2014 6:41:16 AM
Alzheon To Present At Cowen and Company 34th Annual Health Care Conference 3/3/2014 7:47:22 AM
Alzheon Appoints Three Industry And Alzheimer’s Leaders To Board Of Directors 1/8/2014 8:19:39 AM